B-intervention	0	11	Acupuncture
O	12	15	for
O	16	22	breast
O	23	29	cancer
O	29	30	-
O	30	37	related
O	38	48	lymphedema
O	48	49	:
O	50	51	a
O	52	62	randomized
O	63	73	controlled
O	74	79	trial
O	79	80	.

O	81	94	Approximately
O	95	97	20
O	97	98	%
O	99	101	of
O	102	108	breast
O	109	115	cancer
O	116	125	survivors
O	126	133	develop
O	134	140	breast
O	141	147	cancer
O	147	148	-
O	148	155	related
O	156	166	lymphedema
O	167	168	(
O	168	172	BCRL
O	172	173	)
O	173	174	,
O	175	178	and
O	179	186	current
O	187	196	therapies
O	197	200	are
O	201	208	limited
O	208	209	.

O	210	212	We
O	213	221	compared
O	222	233	acupuncture
O	234	235	(
O	235	237	AC
O	237	238	)
O	239	241	to
B-control	242	247	usual
I-control	248	252	care
I-control	253	257	wait
I-control	257	258	-
I-control	258	262	list
I-control	263	270	control
I-control	271	272	(
I-control	272	274	WL
I-control	274	275	)
O	276	279	for
O	280	289	treatment
O	290	292	of
O	293	303	persistent
O	304	308	BCRL
O	308	309	.

B-eligibility	310	315	Women
I-eligibility	316	320	with
I-eligibility	321	329	moderate
I-eligibility	330	334	BCRL
I-eligibility	335	342	lasting
I-eligibility	343	350	greater
I-eligibility	351	355	than
I-eligibility	356	359	six
I-eligibility	360	366	months
O	367	371	were
O	372	382	randomized
O	383	385	to
O	386	388	AC
O	389	391	or
O	392	394	WL
O	394	395	.

O	396	398	AC
O	399	407	included
O	408	413	twice
O	414	420	weekly
O	421	427	manual
O	428	439	acupuncture
O	440	444	over
O	445	448	six
O	449	454	weeks
O	454	455	.

O	456	458	We
O	459	468	evaluated
O	469	472	the
O	473	483	difference
O	484	486	in
O	487	500	circumference
O	501	504	and
O	505	517	bioimpedance
O	518	525	between
O	526	534	affected
O	535	538	and
O	539	549	unaffected
O	550	554	arms
O	554	555	.

O	556	566	Responders
O	567	571	were
O	572	579	defined
O	580	582	as
O	583	589	having
O	590	591	a
O	592	600	decrease
O	601	603	in
O	604	607	arm
O	608	621	circumference
O	622	632	difference
O	633	640	greater
O	641	645	than
O	646	648	30
O	648	649	%
O	650	654	from
O	655	663	baseline
O	663	664	.

O	665	667	We
O	668	672	used
O	673	681	analysis
O	682	684	of
O	685	695	covariance
O	696	699	for
O	700	713	circumference
O	714	717	and
O	718	730	bioimpedance
O	731	743	measurements
O	744	747	and
O	748	754	Fisher
O	754	755	'
O	755	756	s
O	757	762	exact
O	763	765	to
O	766	775	determine
O	776	779	the
O	780	790	proportion
O	791	793	of
O	794	804	responders
O	804	805	.

O	806	811	Among
B-total-participants	812	814	82
O	815	823	patients
O	823	824	,
B-total-participants	825	827	73
O	828	829	(
O	829	831	89
O	831	832	%
O	832	833	)
O	834	838	were
O	839	848	evaluable
O	849	852	for
O	853	856	the
O	857	864	primary
O	865	873	endpoint
O	874	875	(
B-intervention-participants	875	877	36
O	878	880	in
O	881	883	AC
O	883	884	,
B-control-participants	885	887	37
O	888	890	in
O	891	893	WL
O	893	894	)
O	894	895	.

O	896	898	79
O	899	900	(
O	900	902	96
O	902	903	%
O	903	904	)
O	905	913	patients
O	914	922	received
O	923	933	lymphedema
O	934	943	treatment
O	944	950	before
O	951	960	enrolling
O	961	963	in
O	964	967	our
O	968	973	study
O	973	974	;
O	975	977	67
O	978	979	(
O	979	981	82
O	981	982	%
O	982	983	)
O	984	993	underwent
O	994	1001	ongoing
O	1002	1011	treatment
O	1012	1018	during
O	1019	1022	the
O	1023	1028	trial
O	1028	1029	.

O	1030	1032	We
O	1033	1038	found
O	1039	1041	no
O	1042	1053	significant
O	1054	1064	difference
O	1065	1072	between
O	1073	1079	groups
O	1080	1083	for
B-outcome	1084	1087	arm
I-outcome	1088	1101	circumference
I-outcome	1102	1112	difference
O	1113	1114	(
O	1114	1115	0
O	1115	1116	.
O	1116	1118	38
O	1119	1121	cm
O	1122	1129	greater
O	1130	1139	reduction
O	1140	1142	in
O	1143	1145	AC
O	1146	1148	vs
O	1148	1149	.
O	1150	1152	WL
O	1152	1153	,
O	1154	1156	95
O	1156	1157	%
O	1158	1160	CI
O	1161	1162	-
O	1163	1164	0
O	1164	1165	.
O	1165	1167	12
O	1168	1170	to
O	1171	1172	0
O	1172	1173	.
O	1173	1175	89
O	1175	1176	,
O	1177	1178	p
O	1179	1180	=
O	1181	1182	0
O	1182	1183	.
O	1183	1185	14
O	1185	1186	)
O	1187	1189	or
B-outcome	1190	1202	bioimpedance
I-outcome	1203	1213	difference
O	1214	1215	(
O	1215	1216	1
O	1216	1217	.
O	1217	1219	06
O	1220	1227	greater
O	1228	1237	reduction
O	1238	1240	in
O	1241	1243	AC
O	1244	1246	vs
O	1246	1247	.
O	1248	1250	WL
O	1250	1251	,
O	1252	1254	95
O	1254	1255	%
O	1256	1258	CI
O	1259	1260	-
O	1261	1262	5
O	1262	1263	.
O	1263	1265	72
O	1266	1268	to
O	1269	1270	7
O	1270	1271	.
O	1271	1273	85
O	1273	1274	,
O	1275	1276	p
O	1277	1278	=
O	1279	1280	0
O	1280	1281	.
O	1281	1282	8
O	1282	1283	)
O	1283	1284	.

O	1285	1290	There
O	1291	1294	was
O	1295	1299	also
O	1300	1302	no
O	1303	1313	difference
O	1314	1316	in
O	1317	1320	the
B-outcome	1321	1331	proportion
I-outcome	1332	1334	of
I-outcome	1335	1345	responders
O	1345	1346	:
B-iv-bin-percent	1347	1349	17
I-iv-bin-percent	1349	1350	%
O	1351	1353	AC
O	1354	1360	versus
B-cv-bin-percent	1361	1363	11
I-cv-bin-percent	1363	1364	%
O	1365	1367	WL
O	1368	1369	(
O	1369	1370	6
O	1370	1371	%
O	1372	1382	difference
O	1382	1383	,
O	1384	1386	95
O	1386	1387	%
O	1388	1390	CI
O	1391	1392	-
O	1393	1395	10
O	1396	1398	to
O	1399	1401	22
O	1401	1402	%
O	1402	1403	,
O	1404	1405	p
O	1406	1407	=
O	1408	1409	0
O	1409	1410	.
O	1410	1411	5
O	1411	1412	)
O	1412	1413	.

O	1414	1416	No
O	1417	1423	severe
B-outcome	1424	1431	adverse
I-outcome	1432	1438	events
O	1439	1443	were
O	1444	1452	reported
O	1452	1453	.

O	1454	1457	Our
O	1458	1469	acupuncture
O	1470	1478	protocol
O	1479	1487	appeared
O	1488	1490	to
O	1491	1493	be
B-outcome	1494	1498	safe
I-outcome	1499	1502	and
I-outcome	1503	1507	well
I-outcome	1508	1517	tolerated
O	1517	1518	.

O	1519	1526	However
O	1526	1527	,
O	1528	1530	it
O	1531	1534	did
O	1535	1538	not
O	1539	1552	significantly
O	1553	1559	reduce
O	1560	1564	BCRL
O	1565	1567	in
O	1568	1578	pretreated
O	1579	1587	patients
O	1588	1597	receiving
O	1598	1608	concurrent
O	1609	1619	lymphedema
O	1620	1629	treatment
O	1629	1630	.

O	1631	1635	This
O	1636	1643	regimen
O	1644	1648	does
O	1649	1652	not
O	1653	1660	improve
O	1661	1665	upon
O	1666	1678	conventional
O	1679	1689	lymphedema
O	1690	1699	treatment
O	1700	1703	for
O	1704	1710	breast
O	1711	1717	cancer
O	1718	1727	survivors
O	1728	1732	with
O	1733	1743	persistent
O	1744	1748	BCRL
O	1748	1749	.
